We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

209 hedge funds and large institutions have $901M invested in Vir Biotechnology in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

13% more call options, than puts

Call options by funds: $3.04M | Put options by funds: $2.7M

1% more funds holding

Funds holding: 206 → 209 (+3)

4% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 68

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $909M → $901M (-$7.72M)

1.31% less ownership

Funds ownership: 67.13% → 65.83% (-1.3%)

Holders
209
Holders Change
+3
Holders Change %
+1.46%
% of All Funds
3.01%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
71
Reduced
68
Closed
27
Calls
$3.04M
Puts
$2.7M
Net Calls
+$342K
Net Calls Change
-$1M

Top Buyers

1
Bank of America
Bank of America
North Carolina
+$10M
2
Citigroup
Citigroup
New York
+$9.36M
3
Barclays
Barclays
United Kingdom
+$5.8M
4
O
OrbiMed
New York
+$5.49M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.77M

Top Sellers

1
AllianceBernstein
AllianceBernstein
Tennessee
-$27.2M
2
Morgan Stanley
Morgan Stanley
New York
-$19.5M
3
Prudential Financial
Prudential Financial
New Jersey
-$3.29M
4
TC
TwinBeech Capital
New York
-$3.22M
5
BlackRock
BlackRock
New York
-$3.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
176
Tower Research Capital (TRC)
New York
$9.94K -$148K -14,568 -94%
PA
177
Parallel Advisors
California
$8.62K – – –
Daiwa Securities Group
178
Daiwa Securities Group
Japan
$5K – – –
FFA
179
Farther Finance Advisors
California
$4.65K +$265 +26 +6%
CMBA
180
C.M. Bidwell & Associates
Hawaii
$4.06K +$4.08K +401 New
CAL
181
Capital Analysts LLC
Pennsylvania
$3K – – –
VCM
182
Versant Capital Management
Arizona
$2.62K +$387 +38 +17%
FDCDDQ
183
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.53K – – –
IA
184
IFP Advisors
Florida
$2.03K – – –
First Manhattan
185
First Manhattan
New York
$1.94K +$1.96K +192 New
Nisa Investment Advisors
186
Nisa Investment Advisors
Missouri
$1.69K +$1.12K +110 +193%
HCP
187
Hexagon Capital Partners
Arkansas
$1.39K -$397 -39 -22%
MAWCM
188
Mine & Arao Wealth Creation & Management
California
$1.17K – – –
CPG
189
Cornerstone Planning Group
New Jersey
$1.04K – – –
FMII
190
Farmers & Merchants Investments Inc
Nebraska
$608 – – –
PWMG
191
Private Wealth Management Group
New Jersey
$517 – – –
UB
192
UMB Bank
Missouri
$466 +$468 +46 New
PFBT
193
Parkside Financial Bank & Trust
Missouri
$396 – – –
AF
194
Advisornet Financial
Minnesota
$304 -$2.15K -211 -88%
HIA
195
Harbor Investment Advisory
Maryland
$304 – – –
EWA
196
EverSource Wealth Advisors
Alabama
$296 +$356 +35 New
BIA
197
Bell Investment Advisors
California
$274 – – –
JWA
198
JFS Wealth Advisors
Pennsylvania
$264 – – –
ECM
199
Everence Capital Management
Indiana
$217 – – –
BTI
200
Blue Trust Inc
Georgia
$172 +$20 +2 +13%
6 7
8
9 10

VIR Hedge Fund Activity: Q1 2024 in Review

209 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2024, worth a combined $901M — down 0.85% from $909M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new VIR positions and 27 closed out — a net gain of 4 holders — while 71 added to existing stakes and 68 trimmed.

The largest buyer was Bank of America, adding an estimated $10M. The largest seller was AllianceBernstein, cutting an estimated $27.2M.

  • 209 institutional investors held Vir Biotechnology (VIR) as of Q1 2024, up from 206 in Q4 2023.
  • Funds reported $901M of Vir Biotechnology stock for Q1 2024, down 0.85% quarter-over-quarter.
  • 31 funds opened new Vir Biotechnology positions in Q1 2024 and 27 closed out, a net change of +4 holders.
  • The largest Vir Biotechnology buyer in Q1 2024 was Bank of America, an estimated $10M added.
  • The largest Vir Biotechnology seller in Q1 2024 was AllianceBernstein, an estimated $27.2M sold.

Based on aggregated 13F filings for Q1 2024.